Gelişmiş Arama

Basit öğe kaydını göster

Nebivolol can be used for combination therapy in patients with autosomal dominant polycystic kidney disease

dc.contributor.authorKocyigit, Ismail
dc.contributor.authorEroglu, Eray
dc.contributor.authorEcder, Tevfik
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T15:56:33Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T15:56:33Z
dc.date.issued2017
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.urihttps://dx.doi.org/10.1080/14656566.2017.1293653
dc.identifier.urihttp://hdl.handle.net/11446/2331
dc.descriptionWOS: 000395198000013en_US
dc.descriptionPubMed ID: 28234564en_US
dc.description.abstract…en_US
dc.language.isoengen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.identifier.doi10.1080/14656566.2017.1293653en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNebivololen_US
dc.subjectpolycystic kidney diseaseen_US
dc.subjecthypertensionen_US
dc.subjectendothelial dysfunctionen_US
dc.titleNebivolol can be used for combination therapy in patients with autosomal dominant polycystic kidney diseaseen_US
dc.typeletteren_US
dc.relation.journalEXPERT OPINION ON PHARMACOTHERAPYen_US
dc.departmentDBÜen_US
dc.identifier.issue4en_US
dc.identifier.volume18en_US
dc.identifier.startpage455en_US
dc.identifier.endpage455en_US
dc.contributor.authorID0000-0003-2571-7385en_US
dc.contributor.authorID0000-0002-6654-4727en_US
dc.relation.publicationcategoryDiğeren_US
dc.department-temp[Kocyigit, Ismail -- Eroglu, Eray] Erciyes Univ, Div Nephrol, Dept Internal Med, Sch Med, Kayseri, Turkey -- [Ecder, Tevfik] Istanbul Bilim Univ, Div Nephrol, Dept Internal Med, Sch Med, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster